DrugPatentWatch Database Preview

ENJUVIA Drug Profile

« Back to Dashboard

When do Enjuvia patents expire, and when can generic versions of Enjuvia launch?

Enjuvia is a drug marketed by Teva Branded Pharm and is included in one NDA. There are two patents protecting this drug.

The generic ingredient in ENJUVIA is estrogens, conjugated synthetic b. There are three drug master file entries for this compound. Additional details are available on the estrogens, conjugated synthetic b profile page.

Summary for ENJUVIA

US Patents:	2
Applicants:	1
NDAs:	1
Clinical Trials:	2
Formulation / Manufacturing:	see details
DailyMed Link:	ENJUVIA at DailyMed

Generic Entry Opportunity Date for ENJUVIA

NDA:

021443

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for ENJUVIA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Branded Pharm	ENJUVIA	estrogens, conjugated synthetic b	TABLET;ORAL	021443-001	Dec 20, 2004		DISCN	No	No			Y	Y
Teva Branded Pharm	ENJUVIA	estrogens, conjugated synthetic b	TABLET;ORAL	021443-002	Dec 20, 2004		DISCN	No	No			Y	Y
Teva Branded Pharm	ENJUVIA	estrogens, conjugated synthetic b	TABLET;ORAL	021443-004	May 10, 2004		DISCN	No	No			Y	Y

Premature patent expiration for: ENJUVIA

Expiration due to failure to pay maintenance fee

Patent Number	Tradename	Expiration Date
	ENJUVIA

International Patents for ENJUVIA

Country	Document Number	Estimated Expiration
European Patent Office	1267852
Austria	377605
Germany	60131253